The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.
In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.
How this report will benefit you
In this brand new 292-page report you will receive 98 charts– all unavailable elsewhere.
The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Key questions answered by this report:
• Factors Affecting Pricing and Reimbursement Decision
• Pricing Negotiations and Discounts
• Reimbursement Policies
• Role of HEOR and Economic Value Planning
• Drug Patent Expiry and Effects on Pricing
• Cost-Effectiveness Analysis
• This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:
• United States
• Canada
• Germany
• France
• UK
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China
• Discussion on parallel import and its impact in the US and Europe.
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Oncology Pricing, Reimbursement and Market Access. You find data, trends and predictions.
Buy our report today Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Benefits of This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methods of the Study
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Market Overview
2.1. A Brief History of Oncology and Treatments
2.2. Oncology: Treatment and Prevention
3. Global Pricing & Reimbursement of Therapeutic Drugs
3.1 Factors Affecting Pricing & Reimbursement Decision
3.2 Price Negotiations & Discounts
3.3 Pricing of a New Drug
3.4 Reimbursement Policies
4. Economic Evaluations
4.1 Role of HEOR and Economic Value Planning
4.2 Overview of Cost-Effectiveness Analysis
4.3 Drug Patent Expiry & Effects on Pricing
5. Health Technology Assessment (HTA) in Market Access
5.1 Key Benefits of HTA and its Process
5.2 Principle HTA Regulatory Agencies
5.3 Case Study: Brief About United Kingdom’s NICE
6. Global Pharmaceuticals Market Dynamics
6.1. United States (U.S.)
6.1.1. U.S. Healthcare System
6.1.1.1. Healthcare Expenditure
6.1.1.2. Key Formularies
6.1.1.3. Role of Pharmacists in the U.S. Healthcare System
6.1.1.4. Regulatory and Approval Process
6.1.2. Pricing & Reimbursement Process and HTA
6.1.3. Oncology Cost of Treatment in The United States
6.1.4. United States’ Payer Insights
6.1.5. Features of Oncology in the United States
6.2 Canada
6.2.1. Canada Healthcare System
6.2.1.1. Healthcare Expenditure
6.2.1.2. Health Coverage
6.2.1.3. Key Formularies
6.2.1.4. Role of Pharmacists in Canada Healthcare System
6.2.2 Pricing & Reimbursement
6.2.2.1. Pricing of Pharmaceuticals in Canada
6.2.2.2 Reimbursement in Canada
6.2.3 Health Technology Assessment
6.2.4 Oncology Cost of Treatment
6.2.5 Canada Payer Insight
6.2.6 Features of Canadian Healthcare for Oncology
6.3. Europe (EU5)
6.3.1 United Kingdom
6.3.1.1 United Kingdom Healthcare System
6.3.1.1.1. Healthcare Expenditure
6.3.1.1.2. Health Coverage
6.2.1.1.3. Key Formularies
6.2.1.1.4. Role of Pharmacists in the U.K. Healthcare System
6.3.1.2. Pricing & Reimbursement
6.3.1.2.1. Pricing of Pharmaceuticals in the U.K.
6.3.1.2.2. Reimbursement of Pharmaceuticals in the U.K.
6.3.1.3. Health Technology Assessment
6.3.1.4. Cost of Oncology in the United Kingdom
6.3.1.5. U.K. Payer Insight
6.3.1.6. Features of Oncology in the U.K.
6.3.2 Germany
6.3.2.1 Germany Healthcare System
6.3.2.2 Key Organisations in German Healthcare System
6.3.2.3. Healthcare Expenditure
6.3.2.4. Health Coverage
6.3.2.5. Key Formularies
6.3.2.6. Role of Pharmacists in German Healthcare System
6.3.2.7. Pricing & Reimbursement
6.3.2.8. Health Technology Assessment
6.3.2.9 Regulatory & Approval Process
6.3.2.10. Oncology Cost of Treatment in Germany
6.3.2.11. Germany’s Payer Insights
6.3.2.12. Features of RA in Germany
6.3.3 France
6.3.3.1. France Healthcare System
6.3.3.1.1. Healthcare Expenditure
6.3.3.1.2. Health Coverage
6.3.3.1.3. Key formularies
6.3.3.1.4. Role of Pharmacists in France Healthcare System
6.3.3.2. Pricing & Reimbursement
6.3.3.2.1. Reimbursement Process
6.3.3.2.2. Pricing of Pharmaceuticals
6.3.3.3. Health Technology Assessment
6.3.3.4. Oncology Cost of Treatment in France
6.3.3.5. France Payer’s Insight
6.3.3.6. Features of Oncology in France
6.3.4. Italy
6.3.4.1. Italy Healthcare System
6.3.4.1.1. Healthcare Expenditure
6.3.4.1.2. Health Coverage
6.3.4.1.3. Key Formularies
6.3.4.1.4. Role of Pharmacists in Italy Healthcare System
6.3.4.2. Pricing & Reimbursement
6.3.4.2.1. Reimbursement Process
6.3.4.2.2. Pricing Approval Process
6.3.4.3. Health Technology Assessment
6.3.4.4. Oncology Cost of Treatment in Italy
6.3.4.5. Italy Payer’s Insight
6.3.4.6. Features of Oncology in Italy
6.3.5 Spain
6.3.5.1 Spain Healthcare System
6.3.5.1.1. Healthcare Expenditure
6.3.5.1.2. Health Coverage
6.3.5.1.3. Key Formularies
6.3.5.1.4. Role of Pharmacists in Spain Healthcare System
6.3.5.2. Pricing & Reimbursement
6.3.5.2.1. Reimbursement of Pharmaceuticals in Spain
6.3.5.2.2. Pricing of Pharmaceuticals in Spain
6.3.5.3. Health Technology Assessment
6.3.5.4. Oncology Cost of Treatment in Spain
6.3.5.5 Spain Payer Insight
6.3.5.6. Features of Oncology in Spain
6.4. Asia-Pacific
6.4.1 Japan
6.4.1.1. Japan Healthcare System
6.4.1.1.1 Key Formularies
6.4.1.2. Pricing & Reimbursement
6.4.1.3. Health Technology Assessment
6.4.1.4. Oncology Cost of Treatment in Japan
6.4.2 Australia
6.4.2.1 Australia Healthcare System
6.4.2.1.1 Healthcare Expenditure:
6.4.2.1.2 Health Coverage
6.4.2.1.3 Key Formularies
6.4.2.1.4 Role of Pharmacists in Australian Healthcare System
6.4.2.2. Pricing & Reimbursement
6.4.2.3. Health Technology Assessment
6.4.2.4. Oncology Cost of Treatment in Australia
6.4.2.5. Australia’s Payer’s Insight
6.4.2.6. Features of Australian Healthcare for Oncology
6.5. BRIC
6.5.1. Brazil
6.5.1.1. Brazilian Healthcare System
6.5.1.1.2. ANVISA’s Regulatory framework for biological products
6.5.1.2. Brazil Pricing and Reimbursement
6.5.1.2.1. Pricing Process
6.5.1.2.2. Reimbursement Process
6.5.1.3. Health Technology Assessment
6.5.1.4. Cost of Oncology in Brazil
6.5.1.5. Brazil Payer’s Insight
6.5.1.6. Features of Oncology in Brazil
6.5.2. Russia
6.5.2.1. Russia Healthcare System
6.5.2.1.1. Healthcare Expenditure
6.5.2.2. Pricing & Reimbursement
6.5.2.3. Health Technology Assessment
6.5.2.4. Cost of Oncology in Russia
6.5.2.5. Russia Payer’s Insight
6.5.2.6. Features of Oncology in Russia
6.5.3 India
6.5.3.1 India Healthcare System
6.5.3.2 Pricing & Reimbursement
6.5.3.2.1. Pricing of Pharmaceuticals in India
6.5.3.2.2. Reimbursement of Pharmaceuticals in India
6.5.3.3 Cost of Oncology Treatment in India
6.5.3.4 India Payer Insight
6.5.3.5 Features of Oncology in India
6.5.4. China
6.5.4.1. China Healthcare System
6.5.4.1.1. Healthcare Expenditure
6.5.4.1.2. Health Insurance & Coverage in China
6.5.4.2. Pricing & Reimbursement
6.5.4.2.1. Pricing of Pharmaceuticals in China
6.5.4.2.2. Reimbursement of Pharmaceuticals in China
6.5.4.3. Health Technology Assessment (HTA)
6.5.4.4. Oncology Cost of Treatment in China
6.5.4.5. China Payer’s Insight
6.5.4.6. Features of RA in China
7. Parallel Import & Its Impact
7.1. Parallel Import in Europe
7.2. Parallel Import in the U.S.
7.3. Economic aspects in Parallel trade
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Table
Table 2.1: Top 10 Best-selling Oncology Drugs, 2018
Table 2.2: Pipeline Treatments Drugs for Oncology
Table 5.1: Institutions and advisory bodies responsible for HTA activities in EU
Table 6.1: The U.S.: Average ASP for Top Biologic Oncology Drugs
Table 6.2: Cost of Treatment in the U.S. for Oncology drugs (AWP Prices) (USD)
Table 6.3: Key Reimbursement Stakeholders’ in Canada
Table 6.4: Canada- Oncology Drug Price – Unit Ex-Factory Prices ($CAD)
Table 6.5: Canada- Oncology Cost of Treatment ($CAD)
Table 6.6: U.K.: Oncology Drugs Price, 2016-2019 – Unit Ex-Factory Prices (GBP)
Table 6.7: U.K.: Oncology Cost of Treatment (2016-2019)
Table 6.8: Germany Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices (Euro) (2016-2019)
Table 6.9: Germany: Oncology Annual Treatment Cost, 2016-2019
Table 6.10: France: Oncology Cost of Treatment
Table 6.11: Italy Competitor Pricing of Onology Drugs – Unit Ex-factory Prices (€) (2016-2019)
Table 6.12: Italy: Oncology Cost of Treatment
Table 6.13: Spain Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices
(EUR) 2016-2019
Table 6.14: Spain: Oncology Annual Treatment Cost, 2016-2019
Table 6.15: Japan: Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices (¥) (2016-2019)
Table 6.16: Australia Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices (AUD) (2016-2019)
Table 6.17: Brazil Competitor Pricing of Oncology Drugs – Per Pack Ex-factory Prices (BRL) (2016-2019)
Table 6.18: Russia Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices (RUB) (2016-2019)
Table 6.19: India Competitor Pricing of Rheumatoid Arthritis Drugs – Unit Ex-factory Prices (INR) (2016-2019)
Table 6.20: China Competitor Pricing of Oncology Drugs – Unit Ex-factory Prices (CNY) (2016-2019)
List of Figure
Figure 2.1: Estimated Number of New Cases Worldwide in 2018
Figure 5.1: Aspects of HTA for Different Technologies and Interventions
Figure 6.1: U.S.: Key Organisations in the US Healthcare System
Figure 6.2: The U.S. – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.3: The U.S. – National Expenditures (as of %GDP Spending), 2016
Figure 6.4: The U.S.: Market Access Flow in United States
Figure 6.5: The U.S.: Federally Funded Health Insurance Plans
Figure 6.6: The U.S.: Top Oncology Drugs Price Trend in U.S. (AWP in USD) (2016-2019)
Figure 6.7: Canada - Healthcare Structure
Figure 6.8: Canada – National Expenditures (as of %GDP Spending), 2016
Figure 6.9: Canada – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.10: Pricing & Reimbursement in Canada
Figure 6.11: Pathways to Reimbursement in Canada
Figure 6.12: Top Oncology Drugs Price Trend in Canada
Figure 6.13: Canada- Breast Cancer Guideline Pathway
Figure 6.14: U.K. – Healthcare System Structure
Figure 6.15: U.K. – National Expenditures (as of % GDP Spending), 2013-2015
Figure 6.16: Pricing & Reimbursement in the U.K.
Figure 6.17: Health Technology Assessment & Appraisal in the U.K.
Figure 6.18: U.K.: Oncology Drugs Price Trend (GBP), 2016-2019
Figure 6.19: Germany – Healthcare System Structure
Figure 6.20: Key Decision-makers in German Healthcare System
Figure 6.21: Germany – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.22: Germany – Multi-player nature of German Healthcare System
Figure 6.23: Pricing & Reimbursement in Germany
Figure 6.24: Germany Health Technology Assessment
Figure 6.25: Germany: Oncology - Top Drugs Price Trend – Unit List Price, EUR (2016-2019)
Figure 6.26: France Healthcare System Structure
Figure 6.27: France – Healthcare Expenditure (% of GDP Spending), 2013-2016
Figure 6.28: France – National Expenditures (as of %GDP Spending), 2016
Figure 6.29: Pricing & Reimbursement in France
Figure 6.30: Health Technology Assessment in France
Figure 6.31: France: Drug Review & Decision Process:
Figure 6.32: Oncology Drugs Price Trend, (EUR) 2016-2019
Figure 6.33: Italy Healthcare System Structure
Figure 6.34: Italy – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.35: Italy – National Expenditures (as of %GDP Spending), 2016
Figure 6.36: Pricing & Reimbursement in Italy
Figure 6.37: Oncology Drugs Price Trend in Italy, 2016-2019 (EUR)
Figure 6.38: Spain – Healthcare System Structure
Figure 6.39: Spain – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.40: Spain – National Expenditures (% of GDP Spending), 2016
Figure 6.41: Pricing & Reimbursement in Spain
Figure 6.42: Reimbursement of pharmaceuticals in Spain
Figure 6.43: Health Technology Assessment in Spain
Figure 6.44: Spain: Top Oncology Drugs Price Trend, 2016-2019 (EUR)
Top Anti-TNF Drugs Price Trend - Spain
Figure 6.45: Japan – Healthcare Expenditure (% of GDP Spending), 2013-2016
Figure 6.46: Japan – National Expenditures (as of %GDP Spending), 2016
Figure 6.47: Japan Healthcare System Structure
Figure 6.48: Health Technology Assessment in Japan
Figure 6.49: Oncology Drugs Price Trend in Japan
Figure 6.50: Australia – Healthcare System Structure
Figure 6.51: Australia – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.52: Health Technology Assessment & Regulatory and Approval Process in Australia
Figure 6.53: Australia: Oncology Drugs Price Trend
Figure 6.54: Brazil – Healthcare Expenditure (% of GDP Spending), 2013-2016
Figure 6.55: Key Decision-Makers in Brazilian Healthcare System
Figure 6.56: Brazil: ANVISA’s Regulatory Approval Pathway For Biological Products
Figure 6.57: Brazil: Top Oncology Drug Price Trend (2016-2019)
Figure 6.58: Russia Healthcare System Structure
Figure 6.59: Russia – Healthcare Expenditure (% of GDP Spending), 2013-2016
Figure 6.60: Russia – National Expenditures (as of %GDP Spending), 2016
Figure 6.61: Oncology Drugs Price Trend in Russia
Figure 6.62: India – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.63: India Healthcare System Structure Figure 6.62: India – Healthcare Expenditure (% of GDP Spending), 2014-2017
Figure 6.64: Key Decision-Makers in Indian Healthcare System
Figure 6.65: Oncology Drugs Price Trend in India (2016-2019)
Figure 6.66: China: Healthcare System Structure
Figure 6.67: China – Healthcare Expenditure (% of GDP Spending), 2013-2016
Figure 6.68: China – National Expenditures (as of % GDP Spending), 2016
Figure 6.69: Pricing & Reimbursement in China
Figure 6.70: China: Health Technology Assessment
Figure 6.71: Oncology Drugs Price Trend in China
AbbVie
Amgen
Biogen
BMJ Group
Bristol-Myers Squib
Canadian Life and Health Insurance Association, Inc.
Celgene
Genentech
Great West Life
Helpucover Health Insurance
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co.
National Friendly HealthCare
Ono Pharmaceutical, Co.
Pfizer
PruHealth
Roche
Saga Health Insurance
Simply Health
List of Organizations Mentioned in the Report
Agency for Healthcare Research and Quality
American Cancer Society
Centre for Disease Control and Prevention
Centre for Medicare and Medicaid Services
Department of Health Medicines, Pharmacy and Industry Group
Economic Committee for Medical Products
European Medicines Agency
Food and Drug Administration
German Cancer Research Centre
German Federal Ministry of Health
German Medical Association
International Agency for Research on Cancer
Medicines and Healthcare products Regulatory Agency
National Agency for the Safety of Medicines and Health Products
National Association of Statutory Health Insurance Physicians
National Health Authority
National Institute for Clinical Excellence
National Institute for Health and Clinical Excellence
National Institute for Health Research
National Institutes of Health
The Christie Hospital in Manchester
University College London Hospital
WHO
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
